OVOCA BIO PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 EUR | -.--% |
|
-.--% | -.--% |
| 2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | - | Sales 2022 | - | Capitalization | 4.89M 4.56M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -4.65M | Net income 2022 | -5M -4.65M | EV / Sales 2021 | - |
| Net cash position 2021 | 6.59M 6.14M | Net cash position 2022 | 3.7M 3.45M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.23
x | P/E ratio 2022 |
-0.87
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.54% |
More Fundamentals
* Assessed data
More press releases
Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction.
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Calendar
2024-06-27
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +10.44% | 107B | |
| +0.82% | 106B | |
| +6.72% | 23.47B | |
| -13.89% | 21.9B | |
| -6.64% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- OVXA Stock
- OVXA Stock